{"result": {"id": "4ae75b2b-631d-4a4d-afcf-1e8be2bfe82a", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ApoB<|>ORGANIZATION<|>Apolipoprotein B, a protein component of LDL particles that is reduced by cholesterol-lowering drugs>  \n##  \n(\"entity\"<|>LDL-R<|>ORGANIZATION<|>Low-density lipoprotein receptor, targeted by PCSK9 inhibitors to increase cholesterol clearance>  \n##  \n(\"relationship\"<|>PCSK9<|>LDL-R<|>PCSK9 binds to LDL-R leading to its degradation; inhibitors block this interaction<|>9>  \n##  \n(\"relationship\"<|>ApoB<|>LDL-C<|>ApoB is the primary apolipoprotein of LDL particles carrying cholesterol<|>8>  \n##  \n(\"relationship\"<|>依折麦布<|>ApoB<|>Ezetimibe reduces ApoB levels by 11-16% alongside LDL-C reduction<|>7>  \n##  \n(\"relationship\"<|>海博麦布<|>ApoB<|>HaiBo MaiBu likely reduces ApoB levels similarly to ezetimibe<|>7>  \n##  \n(\"relationship\"<|>PCSK9抑制剂<|>LDL-R<|>PCSK9 inhibitors prevent LDL-R degradation to enhance cholesterol clearance<|>9>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166460, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 300, "prompt_tokens": 3714, "total_tokens": 4014, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3648}, "prompt_cache_hit_tokens": 3648, "prompt_cache_miss_tokens": 66}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 0.6 g/次，每日 2 次\n　氟伐他汀 40 mg/次，每日 1 次 洛伐他汀 20 mg/次，每日 1 次 匹伐他汀 1 mg/次，每日 1 次   普伐他汀 20 mg/次，每日 1 次 辛伐他汀 10 mg/次，每日 1 次 依折麦布 10 mg/次，每日 1 次\n海博麦布 10~20 mg/次，每日 1 次\n　　注：LDL?C 低密度脂蛋白胆固醇，PCSK9 前蛋白转化酶枯草溶 菌素 9；a 阿托伐他汀 80 mg 在中国人群中使用的经验不足\n\n\n益 。鉴于我国人群对大剂量他汀类药物耐受性较 差，建议采用中等强度他汀类药物进行治疗 。使用 过程中应密切监测肝肾功能、肌肉症状、新发糖尿 病和出血性卒中等潜在不良反应［41］。常见的非他 汀类降脂药物见表 4。\n　　（2）胆固醇吸收抑制剂：胆固醇吸收抑制剂主  要通过抑制小肠对胆固醇的吸收发挥降胆固醇作  用，主要包括依折麦布和海博麦布等 。单独使用依  折 麦 布 可 使 LDL?C 降 低 10%~18%，ApoB 降 低  11%~16%；与他汀类药物联合使用，可使 LDL?C 进  一步降低 25%［42］。海博麦布是一种由我国自主研  发并拥有自主知识产权的新型选择性胆固醇吸收  抑制剂，其作用机制、用法和降脂疗效等与依折麦  布相似［43］。胆固醇吸收抑制剂主要用于辅助治疗  使用他汀类药物 1~3 个月后 LDL?C 仍未达标的患  者，也可用于他汀类药物不能耐受的患者（可作为  替代或起始联合治疗方案）。 此类药物不良反应轻  微，且多为一过性，主要表现为头痛和消化道症状。 需注意其与他汀类药物联用可导致肝酶升高和肌  痛等不良反应，妊娠期和哺乳期禁用。\n　　（3）前 蛋 白 转 化 酶 枯 草 溶 菌 素 9（proprotein  convertase subtilisin?kexin type 9，PCSK9）抑制剂 ： PCSK9 单克隆抗体是一类新型降胆固醇药物，通过  阻断 PCSK9 与 LDL?R 结合 ，阻止 LDL?R 内化和降\n\n表4    常见的非他汀类降脂药物\n\n种类\t常用药物\t用法和用量\n胆固醇吸收抑制剂\t依折麦布 海博麦布\t口服，10 mg/次，每日 1 次\n口服，10 或 20 mg/次，每日 1 次\nPCSK9 抑制剂\t依洛尤单抗\n　阿利西尤单抗 托莱西单抗\n英克司兰\t皮下注射，140 mg/次，每 2 周 1 次；或 420 mg/次，每 4 周 1 次 皮下注射\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>LDL-C<|>ORGANIZATION<|>Low-density lipoprotein cholesterol, a type of cholesterol targeted by various drugs mentioned in the text>  \n##  \n(\"entity\"<|>PCSK9<|>ORGANIZATION<|>Proprotein convertase subtilisin/kexin type 9, a protein targeted by PCSK9 inhibitors for lowering cholesterol>  \n##  \n(\"entity\"<|>依折麦布<|>ORGANIZATION<|>Ezetimibe, a cholesterol absorption inhibitor used to lower LDL-C levels>  \n##  \n(\"entity\"<|>海博麦布<|>ORGANIZATION<|>HaiBo MaiBu, a domestically developed cholesterol absorption inhibitor similar to ezetimibe>  \n##  \n(\"entity\"<|>阿托伐他汀<|>ORGANIZATION<|>Atorvastatin, a statin drug used for cholesterol management>  \n##  \n(\"entity\"<|>洛伐他汀<|>ORGANIZATION<|>Lovastatin, a statin drug used for cholesterol management>  \n##  \n(\"entity\"<|>匹伐他汀<|>ORGANIZATION<|>Pitavastatin, a statin drug used for cholesterol management>  \n##  \n(\"entity\"<|>普伐他汀<|>ORGANIZATION<|>Pravastatin, a statin drug used for cholesterol management>  \n##  \n(\"entity\"<|>辛伐他汀<|>ORGANIZATION<|>Simvastatin, a statin drug used for cholesterol management>  \n##  \n(\"entity\"<|>依洛尤单抗<|>ORGANIZATION<|>Evolocumab, a PCSK9 inhibitor used for lowering cholesterol>  \n##  \n(\"entity\"<|>阿利西尤单抗<|>ORGANIZATION<|>Alirocumab, a PCSK9 inhibitor used for lowering cholesterol>  \n##  \n(\"entity\"<|>托莱西单抗<|>ORGANIZATION<|>Tolezumab, a PCSK9 inhibitor used for lowering cholesterol>  \n##  \n(\"entity\"<|>英克司兰<|>ORGANIZATION<|>Inclisiran, a PCSK9 inhibitor used for lowering cholesterol>  \n##  \n(\"relationship\"<|>依折麦布<|>LDL-C<|>Ezetimibe reduces LDL-C levels by inhibiting cholesterol absorption<|>8>  \n##  \n(\"relationship\"<|>海博麦布<|>LDL-C<|>HaiBo MaiBu reduces LDL-C levels by inhibiting cholesterol absorption, similar to ezetimibe<|>8>  \n##  \n(\"relationship\"<|>PCSK9<|>LDL-C<|>PCSK9 inhibitors lower LDL-C by preventing LDL receptor degradation<|>9>  \n##  \n(\"relationship\"<|>依洛尤单抗<|>PCSK9<|>Evolocumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol<|>9>  \n##  \n(\"relationship\"<|>阿利西尤单抗<|>PCSK9<|>Alirocumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol<|>9>  \n##  \n(\"relationship\"<|>托莱西单抗<|>PCSK9<|>Tolezumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol<|>9>  \n##  \n(\"relationship\"<|>英克司兰<|>PCSK9<|>Inclisiran is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol<|>9>  \n##  \n(\"relationship\"<|>阿托伐他汀<|>LDL-C<|>Atorvastatin is a statin that lowers LDL-C levels<|>8>  \n##  \n(\"relationship\"<|>洛伐他汀<|>LDL-C<|>Lovastatin is a statin that lowers LDL-C levels<|>8>  \n##  \n(\"relationship\"<|>匹伐他汀<|>LDL-C<|>Pitavastatin is a statin that lowers LDL-C levels<|>8>  \n##  \n(\"relationship\"<|>普伐他汀<|>LDL-C<|>Pravastatin is a statin that lowers LDL-C levels<|>8>  \n##  \n(\"relationship\"<|>辛伐他汀<|>LDL-C<|>Simvastatin is a statin that lowers LDL-C levels<|>8>  \n##  \n(\"relationship\"<|>依折麦布<|>海博麦布<|>Both are cholesterol absorption inhibitors with similar mechanisms<|>7>  \n##  \n(\"relationship\"<|>依折麦布<|>阿托伐他汀<|>Ezetimibe can be combined with statins like atorvastatin for enhanced LDL-C reduction<|>6>  \n##  \n(\"relationship\"<|>海博麦布<|>阿托伐他汀<|>HaiBo MaiBu can be combined with statins like atorvastatin for enhanced LDL-C reduction<|>6>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_99a27685caba3d7c3d7977a1f1bdd761a79517d9253aaf3c93dd124ba05b1fba_v2"}